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Background: In critically ill patients, glucose control with insulin mandates time– and blood–consuming glucose
monitoring. Blood glucose level fluctuations are accompanied by metabolomic changes that alter the composition
of volatile organic compounds (VOC), which are detectable in exhaled breath. This review systematically summarizes
the available data on the ability of changes in VOC composition to predict blood glucose levels and changes in blood
glucose levels.
Methods: A systematic search was performed in PubMed. Studies were included when an association between blood
glucose levels and VOCs in exhaled air was investigated, using a technique that allows for separation, quantification
and identification of individual VOCs. Only studies on humans were included.
Results: Nine studies were included out of 1041 identified in the search. Authors of seven studies observed a significant
correlation between blood glucose levels and selected VOCs in exhaled air. Authors of two studies did not observe a
strong correlation. Blood glucose levels were associated with the following VOCs: ketone bodies (e.g., acetone), VOCs
produced by gut flora (e.g., ethanol, methanol, and propane), exogenous compounds (e.g., ethyl benzene, o–xylene,
and m/p–xylene) and markers of oxidative stress (e.g., methyl nitrate, 2–pentyl nitrate, and CO).
Conclusion: There is a relation between blood glucose levels and VOC composition in exhaled air. These results warrant
clinical validation of exhaled breath analysis to monitor blood glucose levels.
Keywords: Glucose, Monitoring, Volatile organic compound, BreathBackground
Many, if not all, critically ill patients are treated with
insulin at some point during their stay in the intensive
care unit (ICU) [1]. Intensive monitoring of the blood
glucose level is a prerequisite for both efficient and safe
insulin titration in these patients [2]. Current practice in
the ICU holds that glucose levels are monitored manually
through intermittent measurements of the blood glucose
level in central laboratories or using laboratory–based
blood gas analyzers and/or glucose strips at the bedside
[3]. Intermittent manual glucose monitoring however, is
expensive and time and blood consuming [4]. Moreover,
intermittent glucose monitoring lacks the ability to detect* Correspondence: j.h.leopold@amc.uva.nl
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unless otherwise stated.temporal trends, potentially causing dangerous insulin
titration errors in critically ill patients [5].
Glucose is a central molecule in metabolism [6,7]. Indeed,
metabolic pathways are activated to maintain normogly-
cemia when the concentration of glucose changes [6,8].
Changes in the activity of these pathways could result in
changes in production of volatile metabolites. These so–
called volatile organic compounds (VOCs) can be detected
in exhaled breath [9].
We hypothesize that there is an association between
VOCs in exhaled breath and blood glucose levels. Previous
excellent reviews focused on the correlation between glu-
cose and exhaled breath condensate (thus soluble markers)
[10] in diabetes [11,12], but none compared all available
literature or discussed the implications for the ICU popula-
tion. The specific aim of this systematic review is to
provide an overview of the available data on the associationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Flow diagram.
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niques for VOC detection.
Methods
This systematic review was done according to standard
methodology [13,14]. Medline was searched through
Pubmed using the following search terms: (“Blood Gluco-
se”[Mesh] OR “Glucose”[MeSH Terms] OR glucose[tiab])
AND (“Exhalat*” [MeSH Terms] OR “Volatile Organic
Compounds” [Mesh] OR exhal* [tiab] OR Volatile Organic
Compound* [tiab] OR Volatile Compound* [tiab] OR
electronic nose [tiab] OR breath [tiab]. The search was
conducted on the 3rd of January 2014. No limits were used
for year of publication and language. Only human studies
were included, with no restriction on subject health, age,
gender or study setting.
Two independent researchers (JHL, LDB) selected arti-
cles for full–text assessment when the title and abstract
suggested investigating the use of exhaled breath to meas-
ure or estimate blood glucose levels. Articles were only
included if an association between blood glucose levels
and VOCs in exhaled air was investigated. Also, VOC
compositions of exhaled air had to be measured by an
analytical technique that allows for separation, quantifica-
tion and identification of individual VOCs, including gas
chromatography and mass spectrometry (GC–MS), ion
mobility mass spectroscopy (IMS), ion−molecule reaction
mass spectrometry (IMR–MS), proton transfer reaction
(time of flight) mass spectrometry (PTR(−TOF)-MS) and/
or selected ion flow tube mass spectrometry (SIFT–MS).
Data from included studies were extracted and meth-
odological quality was assessed independently by two
researchers (JHL, LDB) using the QUADAS–2 tool for
quality assessment [15]. The tool was adapted to be more
relevant to the included literature. Disagreement between
the two reviewers on inclusion of studies was resolved by
consensus. The adjusted version of QUADAS–2 is pre-
sented in Additional file 1. Extracted data included: 1)
characteristics of the study (design, year of publication
and country of study conduction); 2) characteristics of the
study population (including age, sex distribution and health
status); 3) characteristics of the index test (including
technique and included VOCs); 4) characteristics of the
reference standard (blood glucose); 5) characteristics of the
outcome (including main results and correlation coefficient




The literature search in Pubmed yielded 1041 titles
(Figure 1). After reading titles and abstracts, 1012 arti-
cles were excluded because the topic was outside of the
scope of this review and 29 articles were retained forfull–text assessment. After the exclusion of 20 papers
(5 reviews/non-original studies, 13 on unrelated topics,
2 index test not compliant with inclusion criteria), 9
articles were included in the analysis. Characteristics of
selected articles are presented in Table 1. Five studies in-
cluded healthy non-diabetic subjects, two studies included
Type 1 Diabetes Mellitus (T1DM) subjects, one study
included Type 2 Diabetes Mellitus (T2DM) subjects and
one study included both healthy and T1DM subjects.
Results of the quality assessment using the QUADAS–
2-tool are presented in Table 2. The risk of bias was
considered high for all studies; none of the studies used
a random sample of patients, all using a pre-specified
target group such as T1DM or T2DM patients. The use
of blood gas measurements or central lab measurements
was considered to be the correct reference standard [16].
The adequate reference standard was used in four stud-
ies. Four studies used finger prick measurement, which
increases the possibility of incorrect insulin titration in
clinical practice [16]. Comparing these measurements to
exhaled breath could lead to biased results. However,
none of these studies were excluded from our review.
Point correlation
Authors of seven out of nine studies found a strong cor-
relation between one or more metabolites in exhaled
breath and blood glucose levels, with a mean linear
regression coefficient of 0.82 [range: 0.08-0.98] (Table 1).
However, none of the included studies validated their
results internally (e.g. cross-validation) or externally (e.g.
in an separate validation cohort). A total of ten metabo-
lites have been reported to correlate with blood glucose
Table 1 Characteristics of included studies




Main Results Mean correlation coefficient

















After overnight fast a high
correlation between sensors and
glucose, and acetone, ethanol,
methanol and glucose was found.
These high correlations were not
found after lunch.
Morning: PTR-TOF-MS: Acetone:0.98
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No strong correlation found
between blood glucose and breath
acetone. Breath acetone was found
to be significantly higher in men.
r = 0.003
Minh [22] Clamp study.
Overnight fast.
T1DM subjects were













GCMS: Group A (Ethanol,
acetone, methyl nitrate,










Group A: healthy, mean r of 0.836,
T1DM, mean r of 0.950. B: healthy,
mean r of 0.829, T1DM, mean r of
0.920.
Healthy: r = 0.8325 T1DM: r = 0.935
Turner [21] Clamp study.
Overnight fast.
T1DM subjects
8, T1DM 28 ±
3 years






No strong correlation at baseline.
Linear correlation between acetone
and blood glucose values. Breath
acetone decreased when blood
glucose decreased. In healthy
volunteers the opposite was seen:
Low blood glucose values yield high
acetone values.
r = 0.816(0.598-0.940)
Lee [20] Clamp study.
Healthy subjects

















Best 4 gas model: Ethanol, acetone,
methyl nitrate, ethyl benzene (mean
r of 0.913(0.698-0.977)) 9 samples
per patient
r = 0.913 (0.698-0.977)
Fritsch [19] OGTT. Healthy
volunteers admitted
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glucose and carbon monoxide
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Methyl nitrate had strongest
correlation with blood glucose
levels. Correlation increased with 30-
minute lag time. Ethanol and Acet-
one DID NOT correlate with glucose


















Table 1 Characteristics of included studies (Continued)
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Multiple linear regression analysis
with ethanol and acetone gave an
average r of 0.70.
r = 0.700














The maximal glucose increase was
associated with a significant increase
in exhaled CO concentration. Both
parameters returned to the baseline




















Table 2 Results of QUADAS-2 tool
















? ? × ✓ ✓ ✓ ✓ Single measurements in morning and in
afternoon make prediction of trend impossible.




? × × ✓ × × ✓ Single measurement makes prediction of trend
impossible. Test review bias because reference
standard is used for index test. Possible




? ✓ ✓ ✓ ✓ ✓ ✓ Clamp study design possibly lowers clinical
relevance because of lack of generalizability.
Test review bias because reference standard is
used for index test.
Turner
(2009) [21]
? × ✓ ✓ × × ✓ Small sample size. Clamp study design possibly
lowers clinical relevance because of lack of
generalizability. Test review bias because
reference standard is used for index test.
Lee
(2009) [20]
? × ✓ ✓ ✓ ✓ ✓ Small sample size. Clamp study design possibly
lowers clinical relevance because of lack of
generalizability. Test review bias because
reference standard is used for index test.
Fritsch
(2008) [19]
? ✓ × ✓ ✓ × ✓ Small sample size. OGTT study design possibly
lowers clinical relevance because of lack of
generalizability. Test review bias because
reference standard is used for index test.




? × ✓ ✓ × ✓ ✓ Clamp study design possibly lowers clinical
relevance because of lack of generalizability.
Test review bias because reference standard is
used for index test. Possible reporting error,
results of only one subject mentioned in detail.
Galassetti
(2005) [32]
? × ? ✓ ✓ ✓ ✓ Small sample size. OGTT study design possibly
lowers clinical relevance because of lack of
generalizability. Test review bias because
reference standard is used for index test.




? ✓ × ✓ ✓ × ✓ Small sample size. OGTT study design possibly
lowers clinical relevance because of lack of
generalizability. Possible verification bias
because of incorrect reference standard.
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flora (ethanol, methanol, and propane), exogenous com-
pounds (Ethyl benzene, o-xylene, and m/p-xylene) and
VOCs that reflect oxidative status (methyl nitrate, 2-
pentyl nitrate, and carbon monoxide (CO)) (Table 3).
Authors of two studies did not observe a strong correl-
ation. The first one of those did not find a significant cor-
relation between a single measurement of breath
acetone and blood glucose in T2DM subjects. Authors
of the second study were unable to demonstrate a
strong correlation between glucose levels and exhaled
CO in healthy subjects. Researchers in one of the stud-
ies that did show a strong correlation between breathmetabolites and glucose levels, only observed this after
overnight fast, showing a weak correlation after con-
suming a meal [17].Temporal association
Researchers in seven out of nine studies performed mul-
tiple measurements with an interval ranging from 2.5 to
40 minutes. Two studies had a cross-sectional design
and only performed a single measurement, or two
unpaired measurements. None of the authors of the
included studies reported on the possibility of predicting
glucose trend.




Generated through pathways involving organic peroxy radical (RO2▪) with NO or NO2. Could be
modulated by acute changes in systematic oxidative status [22].
Acetone
[20-22,32]
Derived from acetoacetate and is produced by synthesis and degradation of ketone bodies and is









Not produced by mammalian cells. Likely due to alcoholic fermentation of glucose




Inhaled and partly metabolized by liver, then exhaled at lower concentration. Rapid-onset
hyperglycemia likely suppressed hepatic metabolism causing peaks in exhaled air [20].
M/P-xylene
[20]
Inhaled and partly metabolized by liver, then exhaled at lower concentration. Rapid-onset
hyperglycemia likely suppressed hepatic metabolism causing peaks in exhaled air [20].
Methanol [22] Reflects gut flora activity and therefore responsive to glycemic fluctuations [22].
Methyl nitrate
[22,39]
A small fraction of superoxide ion (O2▪−), a byproduct of oxidative reactions, reacts with nitric oxide
which in turn can react with methanol to eventually form an isomer of Methyl nitrate [39].
O-xylene [20] Inhaled and partly metabolized by liver, then exhaled at lower concentration. Rapid-onset
hyperglycemia likely suppressed hepatic metabolism causing peaks in exhaled air [20].
Propane [22] Reflects gut flora activity and therefore responsive to glycemic fluctuations [22]. N-4 fatty acid Peroxidation
Protein oxidation
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This systematic review identified nine studies that investi-
gated the ability of exhaled breath to measure or estimate
blood glucose levels. A significant correlation between
VOCs in exhaled breath and blood glucose levels was
found in seven studies. These results indicate that there is
an association between the two, although not all studies
are consistent. Researchers in one of these seven studies
only found a strong correlation after overnight fasting of
the subjects and were unable to replicate the results after
a meal [17]. Authors of two negative studies did not find a
strong correlation, possibly due to a different study design
[18] and the VOC (e.g. CO) that was studied [19]. Authors
of the study that included subjects with T2DM did not
show a significant correlation between exhaled VOCs and
blood glucose levels. This study also had a different
(cross-sectional) design. The analytical technique used for
VOC detection did not modify the reported correlation.
None of the studies monitored breath continuously. Also
the glucose trend, thus the temporal association between
glucose and exhaled VOCs, was not explicitly investigated.
However, the data from three longitudinal studies [20-22]
suggest that trends in glucose levels could possibly be
monitored using exhaled breath when measurements are
taken more frequently.
Index tests: exhaled breath analysis
A significant correlation between metabolites in exhaled
breath and blood glucose levels was found using GC-
MS, SIFT-MS, PTR-TOF-MS, a nano-sensing film-based
sensor, and an electrochemical analyzer as analytical
method. GC-MS is considered to be the gold standardfor VOC detection and has shown to have a high sensi-
tivity to identify single VOCs [23]. Therefore, GC-MS is
suitable to accurately quantify a number of different
VOCs in a cross-sectional study. However, the time-
consuming nature of the technique limits use of the device
for real-time and continuous measurements, which ham-
pers clinical application. Other analytical techniques such
as SIFT-MS [22,23] and PTR-TOF-MS [23-25] can also
identify single VOCs and can be used for real-time
continuous measurements. Disadvantages include possible
selection bias [26] and the limitation to the concentration
range that can be detected [25].
The electrochemical analyzers used in selected studies
are two different Smokerlyzer Micro (Bedfont, UK)
devices. These devices measure the amount of CO in
exhaled breath. However, there is a cross sensitivity to
hydrogen [19]. While a correlation between exhaled CO
and glucose levels was found by the researchers of one
study [27], researchers of another study [19] could not
reproduce these findings. Contrasting results may be due
to the high cross sensitivity to hydrogen in the electro-
chemical analyzer used previously [27], which was less
apparent using a newer device [19]. This exemplifies the
importance of an adequate analytical technique that suits
the aim of the study.
An important limitation of the techniques used in
included studies is that none of them was used to con-
tinuously monitor exhaled breath. Continuous analysis
of the exhaled breath was previously described by means
of IMR-MS [28], PTR-MS [24], and electronic nose
[29,30]. After a training phase, electronic noses learn to
recognize specific disease states and can therefore be
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quantify single VOCs, but they do give a rapid, bedside
diagnosis, which, from a clinical perspective, renders this
device attractive. The electronic nose has been used to
discriminate between patients with and without diabetes
[31]. One could postulate that the ability to diagnose
diabetes is partly due to the metabolomic alterations be-
cause of higher blood glucose levels in diabetic patients.
Therefore, electronic nose analysis may complement
mass-spectrometry based techniques for the monitoring
of blood glucose levels in clinical practice, providing sig-
nals based on probabilistic training and validation. Alter-
natively to semi-selective recognition, nanosensors also
rely on specific recognition of certain VOCs [30]. In one
study, an acetone-selective nanomaterial-based sensor
was used alongside PTR-TOF-MS and showed a strong
correlation between acetone, glucose and the sensor [17].
Small size of devices using nanomaterial-based sensors as
compared to spectrometry-based methods facilitates clin-
ical application.
VOCs associated with blood glucose levels
Mechanisms related to the association between VOCs
and glucose levels can be found in Table 3. Acetone
appeared to be associated with blood glucose levels
[17,20-22,32]. As a result of increased synthesis of acetone
and degradation of ketone bodies, acetone is expected to
be higher in diabetics [33]. On the other hand, healthy
humans only have elevated levels of ketone bodies when
fasting or exercising [11]. Therefore, it is more likely to
find a correlation between exhaled acetone and glucose
levels after fasting compared to finding a correlation after
lunch [17]. Acetone possibly is a good marker for glucose
levels in ICU-patients. However, the large variation in
breath acetone levels between subjects [18,34-36] may re-
sult in low accuracy when using acetone cross-sectionally.
VOCs such as ethanol [17,20,22,32], propane [22] and
methanol [17,22] are likely to reflect gut flora activity,
since the metabolism of gut bacteria is responsive to gly-
cemic fluctuations [22,32]. However, we cannot exclude
that other biochemical pathways also contribute to the
production of these compounds. In critically ill patients
on the ICU, the quantity and composition of the gut
microbiome are changing over time and therefore the
amount of VOCs they produce may not be stable [37]
Therefore, these markers are less likely to predict glucose
levels in ICU-patients.
Ethyl benzene [20,22], o-xylene [20] and m/p-xylene
[20] are gasses that are inhaled, partially metabolized by
the liver and subsequently exhaled at lower concentra-
tions [20]. Rapid-onset hyperglycemia likely suppresses
hepatic metabolism, thus causing peak concentrations of
these compounds in exhaled air. Recent evidence sug-
gests that cyclic hydrocarbons such as ethyl benzene andxylene are emitted by the ventilator and tubing [38].
Given that exhaled air is readily accessible for measure-
ments in mechanically ventilated ICU patients, use of ex-
haled air for the prediction of glucose levels is therefore
plausible.
An isomer of methyl nitrate [22,39] is formed when
methanol reacts with nitric oxide, which in turn reacts
with superoxide ion (O2
-), a by-product of oxidative reac-
tions [39]. Furthermore, 2-pentyl nitrate [22] is generated
through pathways involving organic peroxy radical (RO2)
and NO or NO2. This could be modulated by acute
changes in systematic oxidative status [22]. Changes in
CO [27] in exhaled breath are possibly related to oxidative
stress. When glucose levels rise, particularly in diabetic
patients, this can lead to oxidative stress. As a protective
response, heme oxygenase is activated, leading to the posi-
tive modulation of CO on insulin secretion [27]. For critic-
ally ill patients on the ICU however, markers of oxidative
stress will be non-specific for high blood glucose, as they
increase with any form of oxidative stress such as sepsis,
high inspired-oxygen fraction and acute respiratory distress
syndrome [40].
Study design
The observed correlation between blood glucose levels
and exhaled VOCs may be due to the inclusion of T2DM
patients and/or a cross-sectional study design. First,
T2DM influences the responsiveness of the body to
changes in blood glucose levels [41]. This is typically char-
acterized by insulin resistance but may also influence the
formation of ketone bodies and the induction of liver
enzymes. Second, breath acetone levels tend to differ
between T1DM, T2DM, and healthy subjects [18,21,35].
Therefore, a decrease in blood glucose levels may not
induce the same rise in breath acetone levels with different
baseline values and in the context of different co-
morbidities. Finally, in line with the previous point, correc-
tion for baseline differences between subjects cannot be
accomplished with a cross-sectional study design. This is
further acknowledged by the fact that the predictive
algorithm requires calibration for every subject in several
studies [20,22]. Since the relation between exhaled breath
metabolites and blood glucose levels shows high inter-
person variation, a cross-sectional design may not be ideal
for predicting glucose levels using breath metabolites. The
possibility of using a single breath maneuver to estimate
blood glucose levels thus seems implausible. Future studies
may therefore focus on longitudinal measurements in the
same subject.
Five included studies used a clamp study design and 2
studies used an oral glucose tolerance test (OGTT).
Clamp studies and OGTT result in a more or less pre-
dictable course of blood glucose levels. Although a
clamp design is ideal for research purposes and enables
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very different and less predictable. The transition of the
results of these studies to the clinical setting will be a
major challenge for the field of blood glucose estimation
by exhaled breath analysis.
Strengths and limitations
We used a standardized systematic review approach, com-
bining all evidence available. All VOCs that are linked to
changes in glucose levels are discussed and their most
likely biochemical pathways are described. In addition, we
carefully assessed the quality of the included studies.
This systematic review also has an important limitation.
The included studies were highly heterogeneous with
respect to patient selection, exhaled breath sampling and
analysis and blood glucose measurement, limiting the
comparability of the studies. Therefore, we decided to de-
scribe the results separately. Most of the included studies
had a relatively high risk of bias and we found that
included studies did not validate their results. Possibly,
this is inevitable in the early stages of biomedical research
but it hinders strong conclusions. Furthermore, models
can possibly be overfit, yielding overoptimistic results.
Our search only identified one negative study. Negative
studies are often not published leading to publication bias.
None of the studies investigated ICU-patients, while
glucose fluctuations are large and frequent in this popula-
tion [42]. Therefore, we cannot draw firm conclusions on
the use of these methods in ICU-patients. We did try to
identify potential pitfalls for the implementation of these
methods in ICU patients by reviewing the biochemical
pathways for the formation of VOCs.
Finally, the use of exhaled breath to monitor glucose
trends was not discussed in any of the articles. Monitoring
glucose trends (in ICU patients) however, has several po-
tential advantages over using single values. First, trend has
a better predictive value compared to single glucose levels;
recent trend can be used to predict future levels. In ICU
patients, this can lead to improved insulin titration.
Second, because outliers can be filtered out, trend is less
susceptible to random noise. Third, possible bias (con-
stantly predicting values too high/low) will be constant
throughout the trend, having a smaller effect. Potential
disadvantages of using glucose trend are possible lag in
the signal, and the potential of amplification of errors.
Conclusion
In conclusion, a significant association between VOCs in
exhaled breath and blood glucose levels was found in
the majority of studies included in this systematic re-
view. Acetone, carbon monoxide, ethanol, ethyl benzene,
M/P-xylene, methanol, O-xylene, and propane were cor-
related with blood glucose levels. Several potential effect
modifiers were identified for ICU-patients. The includedstudies were performed under highly controlled circum-
stances, which limit generalizability. Our results warrant
clinical validation of exhaled breath analysis for the
monitoring of blood glucose levels in critically ill ICU-
patients.
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